FIRST Faculty

Open Position


+49 (0) 69/798-29801






The GRK 757 is a joint academic and research venture between the Johann Wolfgang Goethe Universityin Frankfurt and the Department of Medical Chemistry at the Karolinska Institute in Stockholm, it´s part of Division I "Inflammation & Pain"


  GRK 757 Eicosanoids
  Division I
  Karolinska Insitute
  European Business School


Institute for Translational Medicine and Therapeutics (ITMAT)

FIRST cooperates with ITMAT (Philadelphia) which fosters relationships between investigators focused on translational biomedical research in all schools at the University of Pennsylvania and in other institutions in the region. It provides educational courses in patient-oriented and translational research, including the newly launched Masters Program in Translational Research (MTR). These training opportunities are partly complementary to the FIRST program. Trainee and exchange programs between FIRST and ITMAT are forseen. Cooperation between FIRST and ITMAT is facilitated by Prof. G. Fitzgerald, Director of ITMAT and member of the Scientific Advisory Board of FIRST.

The Center for Biomedical Innovation (CBI)

The CBI (Boston) aims to identify, research and enable the implementation of innovative methodologies and approaches that transform the discovery, development and delivery of accessible therapeutics, diagnostics and devices. The CBI will accomplish its objectives by creating collaborative teams that bring together key faculties from relevant schools and divisions across MIT and Harvard, as well as their counterparts in government and industry. Cooperation between FIRST and the CBI is facilitated by Dr. F. Douglas who is Executive Director of CBI and Speaker of the Scientific Advisory Board of ZAFES, thus fully aware of the specialities in the German and U.S. graduate school system. As an honorary Professor of the Medical Faculty of Frankfurt University Dr. Frank Douglas also belongs to the teaching body of the university.

Karolinska Institute

The Karolinska Institute, especially the Department of Physiological Chemistry II has a long tradition in eicosanoid research. Pioneering work has been performed by members of the group directed by Professor Bengt Samuelsson, who was awarded the Nobel Prize in 1982 for his discovery and elucidation of essential pathways and modes of action of eicosanoids in inflammation and cancer. Over the last few years, Frankfurt University has brought together an internationally renowned group of scientists to form an Eicosanoid Research Cluster, with interests and expertise that complement those of the Karolinska Institute. The close cooperation between both institutions is highlighted by the establishment of the joint European Research Training Group 757.

The European Business School (ebs)

The EUROPEAN BUSINESS SCHOOL (ebs) in Oestrich- Winkel/Rheingau (30 km from Frankfurt) is the oldest private university of business administration in Germany and is also one of the most highly respected business schools in Europe and has set new standards in the field of business education and executive training. For over 30 years, the ebs has emphasized innovation in teaching, research and university management. The ebs is involved in FIRST Core Curriculum Module 12 dealing with business plan development, marketing and international trends in drug markets.


Existing networks in lipid metabolism and inflammation include the European Research Training Group GRK 757, "Eicosanoids in biology and medicine", which was founded in 2001 together with our partner, the Karolinska Institute in Stockholm. The group (RTG) provides a structured education program for PhD students with the focus on inflammation and pain and covers basic as well as clinical aspects of lipid mediators. The training group is complemented by the Endowed Professorship for Immunopharmacology (Dr. Schleussner Stiftungsprofessur).

Eicosanoids and Nitric Oxide (EICOSANOX)

EICOSANOX is an integrated project funded by the European Commission´s 6th Framework Program and integrates 11 academic institutes and 2 small-medium enterprises. The consortium focuses on eicosanoids and nitric oxide (NO) in physiological and pathological settings. Research is aimed at characterizing the functional genomics and proteomics of the eicosanoid and NO cascades, detailing the molecular mechanisms of signaling and role in disease processes, identifying new genes and potential drug targets as well as developing novel strategies for therapeutic intervention and drug design. The consortium is jointly carrying out an ambitious research and development program spanning all the way "from molecules to patients". The Karolinska Institute and Frankfurt University are the major contractors within EICOSANOX. Within the consortium, Frankfurt University coordinates the EICOSANOX pan-European education program.

The European Vascular Genomics Network (EVGN)

The EVGN is a network of Excellence founded by the European Commission´s 6th Framework Programme and aims to integrate post-genome research into the more established biomedical and biotechnological approaches to cardiovascular disease. The priority areas of the EVGN were chosen because of their importance in pathogenesis and their promise in terms of understanding basic pathophysiological mechanisms as well as development of new diagnostic and treatment modalities. These comprise: 1) early endothelial dysfunction, 2) atherosclerotic plaque instability, and 3) therapeutic angiogenesis. The EVGN has initiated a highly popular summer school program for PhD students which will also open to members of FIRST performing research into cardiovascular diseases.

Diagnostic Center of Acute Leukemia (DCAL)

The DCAL provides connections to European and overseas laboratories working on diagnostics of high-risk acute leukemias. Genetic material of each leukemia patient is being investigated to identify and analyze leukemogenic fusion genes or other genetic changes that causes cancer and classify different leukemia entities. For each leukemia patient molecular markers are established that are used for minimal residual disease monitoring in different European study centers. The Frankfurt DCAL collaborates with all major centers and study groups in UK, France, Czech Republic, Austria, Poland, Switzerland, Italy and Germany. The diagnostic work is organized in the framework of the study groups I-BFM, GMALL and the AMLCG.